Biocircuits Corp., of Sunnyvale, Calif., received U.S.market clearance for its IOS testing instrumentation. Thecompany's first two assays, used to assess thyroidfunction, already were cleared by the FDA.
Oncor Inc., of Gaithersburg, Md., had an FDA advisorypanel recommend against approval of its Inform HER-2/neu breast cancer test. The panel said more data areneeded. Oncor said it intends to address the panel'sconcerns.
Biopool International Inc., of Ventura, Calif., said itsproposed acquisition of Source Scientific, of GardenGrove, Calif., is off. (See BioWorld Today, Nov. 15,1995, p. 3.) Biopool also said it received approval tomarket two chemistry reagent systems used in thediagnosis of liver dysfunction.
Ostex International Inc., of Seattle, said a federal judgeissued an order requiring Boehringer Mannheim, ofIndianapolis, to appear at an arbitration hearing, whereOstex will seek to confirm termination of theiragreement. Ostex said it took the action becauseBoehringer Mannheim failed to market the Osteomarkbone resorption test per the agreement. BoehringerMannheim, which filed a $20 million counterclaim, saidOstex refused to provide materials and support as calledfor in the contract.
* MicroProbe Corp., of Bothell, Wash., completed thesale of its diagnostics business, including its name, toBecton Dickinson and Co., of Franklin Lakes, N.J., for$8.5 million. The deal also helps resolve MicroProbe'spatent dispute with Gen-Probe Inc., of San Diego. Theformer MicroProbe now is called Epoch PharmaceuticalsInc. (See BioWorld Today, Oct. 4, 1995, p. 3.)
(c) 1997 American Health Consultants. All rights reserved.